These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 22801063)

  • 1. Risk-guided therapy: a first step to personalized medicine.
    Zannad F; Koenig W
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):5-6. PubMed ID: 22801063
    [No Abstract]   [Full Text] [Related]  

  • 2. Conclusion.
    Koenig W; Zannad F
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):54-5. PubMed ID: 22801070
    [No Abstract]   [Full Text] [Related]  

  • 3. Do novel biomarkers add to existing scores of total cardiovascular risk?
    De Backer G; Graham I; Cooney MT
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):14-7. PubMed ID: 22801065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The science of risk models.
    Prieto-Merino D; Pocock SJ
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):7-13. PubMed ID: 22801064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical appraisal of trials for validation of 'risk-guided' cardiovascular disease prevention therapy.
    Castro A; Rosillo SO; Alonso A; Pedersen T
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):33-6. PubMed ID: 22801068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation, target population, compliance and barriers to risk guided therapy.
    Tokgozoglu L; Bruckert E
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):37-41. PubMed ID: 22801069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From cardiovascular disease to cardiovascular health: a quiet revolution?
    Labarthe DR
    Circ Cardiovasc Qual Outcomes; 2012 Nov; 5(6):e86-92. PubMed ID: 23170007
    [No Abstract]   [Full Text] [Related]  

  • 8. The female heart is vulnerable to cardiovascular disease: emerging prevention evidence for women must inform emerging prevention strategies for women.
    Wenger NK
    Circ Cardiovasc Qual Outcomes; 2010 Mar; 3(2):118-9. PubMed ID: 20233978
    [No Abstract]   [Full Text] [Related]  

  • 9. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).
    ; ; ; ; ; ; ; ; ; ; ; ; ;
    Eur J Prev Cardiol; 2012 Aug; 19(4):585-667. PubMed ID: 22763626
    [No Abstract]   [Full Text] [Related]  

  • 10. Reducing the cardiovascular disease burden: justified means for getting to the end.
    Bikdeli B; Barreto-Filho JA
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):580-6. PubMed ID: 22811501
    [No Abstract]   [Full Text] [Related]  

  • 11. Performance measures in million hearts: 2 partners' perspective.
    Drozda JP; Holmes DP
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):587-8. PubMed ID: 22811502
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular risk in the Mediterranean area is low: impact on clinical decision-making.
    Rubba P
    Nutr Metab Cardiovasc Dis; 2005 Dec; 15(6):399-401. PubMed ID: 16314225
    [No Abstract]   [Full Text] [Related]  

  • 13. New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?
    Reiner Z
    Eur J Cardiovasc Prev Rehabil; 2011 Oct; 18(5):724-7. PubMed ID: 21945917
    [No Abstract]   [Full Text] [Related]  

  • 14. Best practice for prevention and treatment of cardiovascular disease through an equity lens: a review.
    Beauchamp A; Peeters A; Tonkin A; Turrell G
    Eur J Cardiovasc Prev Rehabil; 2010 Oct; 17(5):599-606. PubMed ID: 20562629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Individualized medicine - our (lack of) understanding].
    Windeler J
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):5-10. PubMed ID: 22325102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk estimation in 2009.
    Kuller LH
    Circ Cardiovasc Qual Outcomes; 2010 Jan; 3(1):4-5. PubMed ID: 20123664
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical validation of genetic markers for improved risk estimation.
    Kessler T; Schunkert H
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):25-32. PubMed ID: 22801067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is prevention a fantasy, or the future of medicine? A panoramic view of recent data, status, and direction in cardiovascular prevention.
    Kones R
    Ther Adv Cardiovasc Dis; 2011 Feb; 5(1):61-81. PubMed ID: 21183531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive risk algorithms in a population setting: an overview.
    Manuel DG; Rosella LC; Hennessy D; Sanmartin C; Wilson K
    J Epidemiol Community Health; 2012 Oct; 66(10):859-65. PubMed ID: 22859516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?
    Sigvant B; Henriksson M; Lundin F; Wahlberg E
    Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):254-61. PubMed ID: 21450673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.